Quick answers
- What is Glipizide used for?
- The FDA-approved label (Glucotrol XL, Roerig, July 21, 2026) says: “GLUCOTROL XL is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. GLUCOTROL XL is a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus Limitations of Use …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Glipizide have a boxed warning?
- No. None of the 98 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Glipizide?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Glipizide been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Glipizide?
- 30 companies list prescription products of Glipizide in the FDA NDC Directory, including A-S Medication Solutions, Bryant Ranch Prepack and NuCare Pharmaceuticals, Inc..
What Glipizide is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
GLUCOTROL XL is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. GLUCOTROL XL is a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus Limitations of Use …
— FDA label: Glucotrol XL, Roerig, effective July 21, 2026. Read the full label on DailyMed →
The FDA has 98 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 98 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet · Tablet, extended release · Tablet, film coated, extended release |
|---|---|
| Route | Oral |
| Prescription products | 140 in the FDA NDC Directory |
| Brand names | Glucotrol XL |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| glipizide 10 mg tablet | Generic | $0.0426 per tablet |
| glipizide 10 mg tablet, extended release | Generic | $0.1253 per tablet |
| glipizide 10 mg tablet, film coated, extended release | Generic | $0.1253 per tablet |
| glipizide 2.5 mg tablet | Generic | $1.25 per tablet |
| glipizide 2.5 mg tablet, extended release | Generic | $0.0982 per tablet |
| glipizide 2.5 mg tablet, film coated, extended release | Generic | $0.0982 per tablet |
| glipizide 5 mg tablet | Generic | $0.0328 per tablet |
| glipizide 5 mg tablet, extended release | Generic | $0.0759 per tablet |
| glipizide 5 mg tablet, film coated, extended release | Generic | $0.0759 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- A-S Medication Solutions21 products
- Bryant Ranch Prepack17 products
- NuCare Pharmaceuticals, Inc.11 products
- Preferred Pharmaceuticals Inc.10 products
- Remedyrepack Inc.9 products
- PD-Rx Pharmaceuticals, Inc.8 products
- Northwind Health Company, LLC7 products
- Proficient Rx LP6 products
- AiPing Pharmaceutical, Inc.5 products
- Aphena Pharma Solutions - Tennessee, LLC5 products
- American Health Packaging4 products
- Advagen Pharma Limited4 products
- NorthStar Rx LLC3 products
- Rising Pharma Holdings, Inc.3 products
- Aurobindo Pharma Limited3 products
- Golden State Medical Supply, Inc.2 products
- ANI Pharmaceuticals, Inc.2 products
- Advanced Rx of Tennessee, LLC2 products
- AvPAK2 products
- St. Mary's Medical Park Pharmacy2 products
- Actavis Pharma, Inc.2 products
- Apotex Corp.2 products
- Coupler LLC2 products
- Legacy Pharmaceutical Packaging, LLC2 products
- NCS HealthCare of KY, LLC dba Vangard Labs2 products
- Oxford Pharmaceuticals, LLC2 products
- Cardinal Health 107, LLC1 product
- Roerig1 product
- TruPharma, LLC1 product
- Major Pharmaceuticals1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA020329 GLUCOTROL XL | Pfizer | April 26, 1994 | 22, latest August 3, 2021 2021: Manufacturing (CMC) · 2018: Labeling · 2017: Labeling |
Generic approvals (9)
- ANDA074378Oxford Pharms · November 28, 1994
- ANDA074223Watson Labs Teva · February 27, 1995
- ANDA074305Aiping Pharm Inc · April 7, 1995
- ANDA074497Ani Pharms · August 31, 1995
- ANDA075795Apotex · June 13, 2001
- ANDA204720Unique · December 29, 2016
- ANDA206928Aurobindo Pharma · May 12, 2017
- ANDA203499Zydus Pharms · July 16, 2018
- ANDA214874Rubicon Research · October 3, 2023
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Glucotrol XL, Roerig, effective July 21, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →